
Capital Markets

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

[!\[\]\(666e09182d4cd268646ea700ea60dcdf_img.jpg\) DOWNLOAD CAPITAL MARKETS FACT SHEET](#)

WilmerHale represents both issuers and investment banking firms in initial public offerings (IPOs), follow-on public offerings, PIPEs (private investments in public equity) and other private placements, cross-border offerings, Rule 144A offerings, and spin-off, carve-out and SPAC transactions. We are one of the world's premier law firms for IPOs, and have led the eastern United States in handling IPOs—as both issuers' and underwriters' counsel—over the past 25 years. In 2023, we handled more than 60 public offerings, Rule 144A placements, PIPE financings, and other equity and debt capital markets transactions, raising in excess of \$35 billion for leading companies in life sciences, technology, financial services and various other industries. Since 2013, we have served as counsel in over 600 capital markets transactions with total proceeds of approximately \$300 billion. Our clients range from emerging companies to established public companies and our lawyers understand the unique demands of complicated securities transactions across industries. We help our clients plan and complete the offering process effectively and efficiently, and no other firm is as well positioned to quickly grasp the subject matter and execute a deal that works from the start.

Key Contacts



Lisa Firenze

PARTNER

✉ lisa.firenze@wilmerhale.com

📍 NEW YORK

☎ + 1 212 937 7263



Brian A. Johnson

PARTNER

✉ brian.johnson@wilmerhale.com

📍 NEW YORK

☎ + 1 212 937 7206

Related Solutions

Corporate Governance and
Disclosure

Financial Services

Private Equity

Debt Finance

Investment Management

Tax

Emerging Company and
Venture Capital

Life Sciences

Technology

Areas of Focus

Initial Public Offerings: Bringing
Order to Chaos

Representing Issuers:
Knowing What the Issuer is
Thinking

Regulatory Issues: Avoiding
the Pitfalls

IPO Alternatives: When
Convention Isn't the Best Path

Private Offerings: Initial
Purchasers and Placement
Agents

Follow-On Public Offerings:
Complicated, Creative, Fast

Cross-Border Offerings:
International Scope

Experience

INITIAL PUBLIC OFFERINGS – ISSUERS

Representing issuers, including Acacia Communications, Aileron Therapeutics, Akouos, Apellis Pharmaceuticals, Arsanis, Arvinas, Blue Apron, Casa Systems, Constellation Pharmaceuticals, Decibel Therapeutics, Dyne Therapeutics, EverQuote, Fulcrum Therapeutics, Generation Bio, IMARA, Inozyme Pharma, Kala Pharmaceuticals, Pandion Therapeutics, Schrödinger, Stealth BioTherapeutics, Syros Pharmaceuticals, Translate Bio and Trevi Therapeutics, in initial public offerings.

INITIAL PUBLIC OFFERINGS – UNDERWRITERS

Representing underwriters in initial public offerings, including those of Amylyx Pharmaceuticals, Arcellx, CinCor Pharma, Crescera Capital Acquisition Corp., Icosavax, Ikena Oncology, Rallybio and Theseus Pharmaceuticals.

FOLLOW-ON PUBLIC OFFERINGS AND PIPE PLACEMENTS

Representing companies, including Agios Pharmaceuticals, Akebia Therapeutics, Apellis Pharmaceuticals, AVEO Pharmaceuticals, Casella Waste Systems, Catabasis Pharmaceuticals, Conformis, Curis, Danaher, Editas Medicine, Epizyme, Farmer Mac, Franklin Street Properties, Infinity Pharmaceuticals, Iterum Therapeutics, Kala Pharmaceuticals, Nightstar Therapeutics, Ocular Therapeutix, PAR Technology, Sage Therapeutics, Solid Biosciences, Spark Therapeutics, State Street, Tetrphase Pharmaceuticals and WEX, in follow-on public offerings and PIPE placements of common and preferred stock.

SPACS (SPECIAL PURPOSE ACQUISITION COMPANIES)

Representing private companies in SPAC business combinations, as well as SPACs and their sponsors in IPOs and business combinations. We also represent private equity, venture capital, family offices and other investors in PIPEs and other SPAC-related investments, and investment banks acting as underwriters, financial advisors and placement agents in SPAC transactions. Our SPAC practice draws on our strengths in capital markets and M&A, and our extensive experience working with growth companies in industry sectors such as healthcare and life sciences, technology, fintech, cleantech, media and entertainment, aviation, energy and others. SPAC transactions in which we have been involved on behalf of our clients have included, among others, Thoma Bravo Advantage/ironSource, Longview Acquisition/Butterfly Network, Vesper Acquisition/HydrFacial, Falcon Capital/Sharecare and HighCape/Quantum SI.

CONVERTIBLE NOTES AND OTHER EQUITY-LINKED SECURITIES

Representing issuers, including Akamai Technologies, Apellis Pharmaceuticals, Danaher, Fortive, Karyopharm Therapeutics, MicroStrategy, PTC Therapeutics and TechTarget in Rule 144A placements and public offerings of convertible notes and other equity-linked securities.

INVESTMENT GRADE AND HIGH-YIELD NOTES

Representing issuers, including Analog Devices, Danaher, Discovery, Emergent BioSolutions, Entegris, Houghton Mifflin Harcourt, Huntington Ingalls Industries, Intercept Pharmaceuticals, Medtronic, PerkinElmer, State Street, S&P Global, Thermo Fisher Scientific and WEX, in Rule 144A placements and public offerings of investment grade and high-yield notes.

Recognition



Recognized Among the Best for Capital Markets

Chambers USA

2020-2023



Named a First-Tier National Firm for Securities/Capital Markets Law

U.S. News - Best Lawyers®

2020-2024



Recognized as a Leading Firm for Capital Markets

The Legal 500 United States

2020-2023

- *Chambers USA Guide* – Ranked WilmerHale in Massachusetts for Capital Markets for the last 4 years, in Massachusetts for Corporate/M&A for the last 19 years, and in Washington DC for Corporate/M&A & Private Equity for the last 17 years.
- *Chambers Global* – Recognized 25 WilmerHale lawyers and 30 practice areas in their 2023 edition.
- *Best Lawyers in America* – Recognized 121 WilmerHale partners for 2024, naming 9 as “Lawyers of the Year.”
- *U.S. News - Best Lawyers®* – Recognized in the 2010–2024 “Best Law Firms” rankings. In the 2024 rankings, our corporate, mergers and acquisitions, and venture capital law practices were ranked in the first tier nationally and in Boston, and our corporate law practice was also ranked in the first tier in Colorado, New York and Washington DC. Our securities/capital markets law practice was ranked in the first tier nationally and in Washington DC. Our technology law practice was also ranked in the first tier in Boston.
- *The Legal 500 United States* – Regularly recognizes WilmerHale’s Capital Markets practice among top law firms for our work in the areas of Debt—Advice to Issuers, Equity Offerings—Advice to Issuers, Equity Offerings—Advice to Managers, most recently in 2023.
- *LMG Life Sciences* – Named WilmerHale and 21 of its lawyers among the nation’s leading life sciences practitioners for the 11th consecutive year. LMG has also ranked the firm in its 2012–2023 editions in corporate, licensing and collaboration, M&A, venture capital and several other practice areas, and named many WilmerHale lawyers “life sciences stars.”

- *Law360* – Named WilmerHale a Technology Practice Group of the Year in 2022, making it the fourth year the firm has received this recognition. This award recognizes the firm’s key role in the significant matters that made headlines and changed the legal landscape within the past year.
- *Super Lawyers* – Our corporate lawyers are consistently recognized as “Super Lawyers” and “Rising Stars” in multiple jurisdictions.